Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) announced its quarterly earnings data on Monday. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03), Zacks reports. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The firm had revenue of $27.87 million during the quarter, compared to analysts’ expectations of $23.50 million.

Gyre Therapeutics Price Performance

Shares of NASDAQ:GYRE opened at $8.57 on Wednesday. The business has a 50-day moving average price of $11.29 and a 200 day moving average price of $12.25. Gyre Therapeutics has a 12-month low of $8.26 and a 12-month high of $19.00.

Analyst Ratings Changes

Separately, Noble Financial started coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating on the stock.

Insider Buying and Selling

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now directly owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders sold 36,054 shares of company stock valued at $409,057. 19.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Gyre Therapeutics

An institutional investor recently raised its position in Gyre Therapeutics stock. Bank of America Corp DE lifted its stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 40.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,937 shares of the company’s stock after buying an additional 1,996 shares during the quarter. Bank of America Corp DE’s holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.